On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Learn more about access and coverage options from an Otezla® (apremilast) field reimbursement manager
Main Contact Information
One Amgen Center Drive
Thousand Oaks, CA 91320-1789
Medical questions or adverse event reports can be directed to Amgen Inc. Medical Information at:
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations